These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7884654)

  • 1. Electrophoretic mobility of salbutamol drug powder in mixed propellant solvents.
    Sandström KB; Eriksson PM; Rosenholm JB
    J Pharm Sci; 1994 Oct; 83(10):1380-5. PubMed ID: 7884654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The distribution of oleic acid between salbutamol base drug and different propellant blends.
    Eriksson PM; Sandström KB; Rosenholm JB
    Pharm Res; 1995 May; 12(5):715-9. PubMed ID: 7479558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A microcalorimetric investigation of the interaction of surfactants with crystalline and partially crystalline salbutamol sulphate in a model inhalation aerosol system.
    Blackett PM; Buckton G
    Pharm Res; 1995 Nov; 12(11):1689-93. PubMed ID: 8592671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM; MacRitchie HB; Marriott C; Martin GP
    Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of flow properties of dry powder inhalation of salbutamol sulfate with lactose carrier.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Leuenberger H
    Chem Pharm Bull (Tokyo); 2001 Oct; 49(10):1326-30. PubMed ID: 11605663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation pre-screening of inhalation powders using computational atom-atom systematic search method.
    Ramachandran V; Murnane D; Hammond RB; Pickering J; Roberts KJ; Soufian M; Forbes B; Jaffari S; Martin GP; Collins E; Pencheva K
    Mol Pharm; 2015 Jan; 12(1):18-33. PubMed ID: 25380027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Apr; 52(4):444-6. PubMed ID: 15056961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigations on particle surface characteristics vs. dispersion behaviour of L-leucine coated carrier-free inhalable powders.
    Raula J; Thielmann F; Naderi M; Lehto VP; Kauppinen EI
    Int J Pharm; 2010 Jan; 385(1-2):79-85. PubMed ID: 19879344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug form selection in albuterol-containing metered-dose inhaler formulations and its impact on chemical and physical stability.
    Tzou TZ; Pachuta RR; Coy RB; Schultz RK
    J Pharm Sci; 1997 Dec; 86(12):1352-7. PubMed ID: 9423144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders.
    Raula J; Lähde A; Kauppinen EI
    Int J Pharm; 2009 Jan; 365(1-2):18-25. PubMed ID: 18789380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenbergerb H
    Chem Pharm Bull (Tokyo); 2003 Dec; 51(12):1455-7. PubMed ID: 14646332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Inagaki Y; Todo H; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):938-42. PubMed ID: 15304985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
    Iida K; Hayakawa Y; Okamoto H; Danjo K; Luenberger H
    Chem Pharm Bull (Tokyo); 2004 Mar; 52(3):350-3. PubMed ID: 14993760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of SCF-engineered particle-based lactose blends in passive dry powder inhalers.
    Schiavone H; Palakodaty S; Clark A; York P; Tzannis ST
    Int J Pharm; 2004 Aug; 281(1-2):55-66. PubMed ID: 15288343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving aerosolization of drug powders by reducing powder intrinsic cohesion via a mechanical dry coating approach.
    Zhou QT; Qu L; Larson I; Stewart PJ; Morton DA
    Int J Pharm; 2010 Jul; 394(1-2):50-9. PubMed ID: 20435112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an impinging jet for dispersion of dry powder inhalation aerosols.
    Wang Z; Lange CF; Finlay WH
    Int J Pharm; 2004 May; 275(1-2):123-31. PubMed ID: 15081143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
    Müller T; Krehl R; Schiewe J; Weiler C; Steckel H
    Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler®.
    Hoe S; Young PM; Traini D
    Drug Dev Ind Pharm; 2011 Nov; 37(11):1365-75. PubMed ID: 21554161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.